TVTX
Travere Therapeutics, Inc.
Biotechnology · Healthcare · United States
61.43
close · 2026-08-13
value
29
cheaper than peers29
quality
26
stronger fundamentals26
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 11.19× | 75 |
| price to sales | 10.88× | 54 |
| EV to EBITDA | 321.71× | 7 |
| price to book | 57.52× | 6 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 55.6% | 62 |
| operating margin | -29.0% | 61 |
| return on equity | -69.4% | 25 |
| debt to equity | 331.9% | 9 |
4 of 4 measures available
Facts
| market cap | $6B |
| free cash flow | -$51.2M |
| employees | 497 |
| first trade | 2012-11-08 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-05 |